Arcus Biosciences, Inc. reported $117M of revenue over the trailing twelve months, −55% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $117M (to Q2 2026). Net income: −$460M, trailing twelve months to Q2 2026. Free cash flow: −$475M, trailing twelve months to Q2 2026. Operating margin: −478%, trailing twelve months to Q2 2026.

RCUSArcus Biosciences, Inc.

Healthcare

$24.39+97% 1Y

$24.39

$12.3752 weeks$31.57

RCUS as reported

Arcus Biosciences, Inc. reported $117M of revenue over the trailing twelve months, −55% on the year before. 10 reported series are charted on this page, each one as filed.

$117M

Revenue, trailing twelve months · to Q2 2026 · −55% against the twelve months before

Net income: −$460M
Net income · +54% year on year · trailing twelve months to Q2 2026
Free cash flow: −$475M
Free cash flow · +39% year on year · trailing twelve months to Q2 2026
Operating margin: −478%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for RCUS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$117M	−55%	Q2 2026
Net income	−$460M	+54%	Q2 2026
EPS	−$3.91	+23%	Q2 2026
Operating margin	−478%	n/a	Q2 2026
Net margin	−454%	n/a	Q2 2026
ROE	−76%	n/a	Q2 2026
ROA	−38%	n/a	Q2 2026
ROIC	165%	n/a	Q2 2026
Free cash flow	−$475M	+39%	Q2 2026
P/E	35.6	n/a	Q3 2022 · 15 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.